Vanda Pharmaceuticals to Present at J.P. Morgan Healthcare Conference on January 15, 2026
Written by Emily J. Thompson, Senior Investment Analyst
Source: Newsfilter
Updated: 48 minutes ago0mins
- Conference Participation: Vanda Pharmaceuticals will present at the J.P. Morgan Healthcare Conference on January 15, 2026, at 9:00 a.m. Pacific Time, which is expected to draw investor interest in its innovative therapies.
- Online Access: The presentation will be accessible live on Vanda's corporate website, requiring investors to register and download necessary software 15 minutes in advance, demonstrating the company's commitment to transparency and investor relations.
- Archive Availability: An archived link will be available for approximately 30 days post-conference, allowing investors who could not attend live to review the presentation, thereby enhancing communication between the company and its investors.
- Company Background: Vanda Pharmaceuticals focuses on developing and commercializing innovative therapies to address high unmet medical needs and improve patient quality of life, showcasing its leadership and social responsibility in the biopharmaceutical sector.
VNDA.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on VNDA
Wall Street analysts forecast VNDA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VNDA is 15.50 USD with a low forecast of 11.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 6.750
Low
11.00
Averages
15.50
High
20.00
Current: 6.750
Low
11.00
Averages
15.50
High
20.00
Truist
Joon Lee
Hold
maintain
$20 -> $36
2025-11-10
Reason
Truist
Joon Lee
Price Target
$20 -> $36
2025-11-10
maintain
Hold
Reason
Truist analyst Joon Lee raised the firm's price target on AnaptysBio (ANAB) to $36 from $20 and keeps a Hold rating on the shares. The company's Q3 benefitted from $50M in Jemperli milestones and growing royalties, with another $75M in milestones expected in Q4, the analyst tells investors in a research note. Near-term catalysts for the stock include Phase 2 UC update in November-December and Vanda's (VNDA) imsidolimab BLA submission in Q4 for GPP, which is tied to milestones for AnaptysBio, the firm added.
B. Riley
NULL -> Buy
initiated
$11
2025-11-05
Reason
B. Riley
Price Target
$11
2025-11-05
initiated
NULL -> Buy
Reason
B. Riley initiated coverage of Vanda Pharmaceuticals with a Buy rating and $11 price target. The firm says Vanda is a commercial-stage turnaround story trading at a "historic discount." The company is heading into two potential approvals within three months and "clearing of multiple overhangs that have kept investors on the sidelines," the analyst tells investors in a research note. It believes the stock's current negative enterprise value represents an attractive entry point.
Cantor Fitzgerald
Overweight
initiated
$13
2025-05-14
Reason
Cantor Fitzgerald
Price Target
$13
2025-05-14
initiated
Overweight
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$20
2025-04-01
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$20
2025-04-01
Reiterates
Strong Buy
Reason
See All Ratings
About VNDA
Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on the development and commercialization of therapies to address unmet medical needs and improve the lives of patients. The Company’s commercial portfolio consist of three products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome (SMS) and PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Tradipitant, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
Why did the FDA extend the re-review timeline for tradipitant?
What were the safety concerns leading to the initial clinical hold on tradipitant?
How might the FDA's decision on tradipitant impact Vanda's stock performance?
Will tradipitant become the first new motion sickness treatment in 40 years?